Clinical Trials

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05951179 2026-01-27

ADVANCED-2

131 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07283835 2026-01-21

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

16 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

90 enrolled

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06663137 2025-06-13

HGNMIBC

70 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04387461 2024-09-25

CORE-001

35 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT05943379 2023-07-13

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

85 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03519256 2023-06-01

CheckMate 9UT

Phase 2 Terminated

142 enrolled 20 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03719300 2020-08-19

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Phase 2 Terminated

32 enrolled 12 charts

Non-Muscle Invasive Bladder Neoplasms

NCT04498702 2020-08-13

Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy

41 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT01687244 2017-07-24

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

40 enrolled 18 charts

Non-Muscle Invasive Bladder Neoplasms

NCT01731652 2015-02-10

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

12 enrolled